The Food and Drug Administration ultimately denied ImClone 's drug application in December 2001 , saying that an Erbitux clinical trial was deficient .
The U.S. Food and Drug Administration rejected ImClone 's original application in December 2001 , saying the trial had been sloppily conducted .
The Bush administration wants the measure approved by June 3 , when the existing oil-for-food program is up for renewal .